Eli Lilly’s Cyramza has hit its primary goal in a late-stage study showing extended progression-free survival in patients with gastric cancer, but the drug failed to improve overall survival, a secondary endpoint.
News
Twenty percent of millennium generation is obese, study finds
Twenty percent of young people born in the UK at the turn of the century were obese by the age of 14, while a further 15 percent were found to be overweight, according to data from UCL’s Millennium Cohort Study
Tecentriq/Avastin combo hits progression-free survival target
Roche unit Genentech has announced that a Phase III study assessing a combination of Tecentriq and Avastin for advanced or metastatic renal cell carcinoma achieved its co-primary endpoint of progression-free survival.
NICE nods for AbbVie in hep C and Novartis in lung cancer
Novartis’ Zykadia and AbbVie’s Maviret get positive recommendations
Roche lung cancer combo doubles PFS rates
37 percent of patients had PFS for a year with Tecentriq and Avastin plus chemotherapy
More than 2,000 immune-oncology drugs now in development
Could lead to “unparalleled” advances in the field
Roche’s Tecentriq available via CDF
Roche’s Tecentriq will be available on the NHS in England via the Cancer Drugs Fund for certain patients with metastatic urothelial carcinoma
Novartis’ Kisqali shows PFS benefit in premenopausal breast cancer
Novartis has unveiled Phase III data showing that partnering Kisqali with an endocrine therapy significantly prolonged progression-free survival compared to an endocrine therapy alone in patients with breast cancer.
Avastin wins full green light for glioblastoma
Roche group Genentech has announced full US approval for Avastin for the treatment of adults with glioblastoma that progressed following prior therapy.
Winter could ‘break the backbone’ of the NHS
Health service experts are warning that the NHS could be “sorely tested” in the coming months as it is already running at near maximum capacity with “severe pressure” on the horizon.
Roche links with UK gov on digital pathology services
The UK Government is in discussions with Roche Diagnostics and partners to support the mainstream implementation of digital pathology services across the NHS.
Drugmakers line up to invest in UK life sciences
GlaxoSmithKline and AstraZeneca have announced significant investment in the UK as part of the government’s sector deal for the life sciences industry.
NHS use of Roche’s Roactemra turned down for giant cell arteritis
It is looking unlikely that patients with giant cell arteritis will get NHS access to Roche’s Roactemra, after the drug was turned down by cost regulators in draft guidelines.
NICE says ‘no’ to Novartis’ AML drug Rydapt
Novartis’ Rydapt , the first and only targeted therapy approved in Europe for FLT3-mutated acute myeloid leukaemia (AML), has been rejected for NHS use by the National Institute for Health and Care Excellence.
Shire, Rani to develop oral factor VIII therapy
Shire and Rani Therapeutics have signed a deal to work on developing an orally-delivered therapy for patients with hemophilia A.
